Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zolbetuximab monotherapy in advanced gastric/esophageal cancer
NCT01197885Phase 2Completed
- Sponsor
- Ganymed Pharmaceuticals
- Start
- Sep 2010
- Primary completion
- Aug 2015
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 5
01
Overview
A Phase 2 trial of zolbetuximab in gastric adenocarcinoma, esophageal adenocarcinoma (EAC), gastroesophageal junction adenocarcinoma, sponsored by Ganymed Pharmaceuticals. Started Sep 2010; status: completed.
02
Drugs
zolbetuximab
03
Conditions
gastric adenocarcinomaesophageal adenocarcinoma (EAC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT01197885.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01197885.